From Yahoo Finance: 2025-06-02 07:45:00

Investing in stocks for the long term remains a smart move despite market volatility. CRISPR Therapeutics and Regeneron Pharmaceuticals offer potential for patient investors in the biotech space. CRISPR’s Casgevy gene editing therapy faces challenges but has significant revenue potential. Regeneron faces biosimilar competition but has strong growth drivers like Eylea HD and Dupixent.

Despite some concerns, CRISPR Therapeutics shows promise with its gene-editing therapies like Casgevy and other potential treatments. Regeneron, while facing competition, has strong growth drivers in Eylea HD and Dupixent. Both companies have potential for future growth and could be worth considering for long-term investment.

Read more: The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip